{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-144604","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.525139+00:00","generated_at":"2026-05-15T07:01:13.394511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jaguar Health FY2025 net loss widens to $53.6M; enters Future Pak deal for non-dilutive capital; Nasdaq appeal pending","bullets":["Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).","Net loss attributable to common stockholders FY2025 $53.6M vs $38.5M; loss from operations $45.9M.","Mytesi prescription volume down 3.7% in 2025 vs 2024; Q4 2025 down 12.2% YoY.","Entered license agreement with Future Pak Jan 2026: $16M up-front non-dilutive capital, $2M additional upon conditions; FP to commercialize Mytesi and Canalevia-CA1.","Received Nasdaq noncompliance notice; appeal hearing April 7, 2026; delisting stayed pending decision."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-144604","json":"https://secwatch.observer/filing/0001193125-26-144604.json","markdown":"https://secwatch.observer/filing/0001193125-26-144604.md","text":"https://secwatch.observer/filing/0001193125-26-144604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/0001193125-26-144604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/d111491d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:01:13.394511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b148cc8d956f9d290e77af53c9015c9752583644","claim":"Jaguar Health, Inc. reported year ended December 31, 2025 results: revenue $11.5 million, net income $53.6 million net loss, EPS ($24.27) per share.","evidence_excerpt":"the total net revenue in the fourth quarter of 2024, which totaled approximately $3.5 million. • In 2025, approximately $11.2 million out of the Company’s total net revenue of $11.5 million was generated by sales of Mytesi and Canalevia-CA1. Under the terms of the license agreement Jaguar entered with Future Pak (“FP”) in January 2026, FP will be responsible for all","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/0001193125-26-144604-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Revenue","value":"$11.5 million"},{"label":"Net income","value":"$53.6 million net loss"},{"label":"EPS","value":"($24.27) per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}